STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
Infection Prevention | STERIS leads in healthcare infection control, with strategic focus driving growth in sterilization and procedural products amid increasing demand |
Financial Resilience | Q1 FY2025 surpasses expectations with $1.28B revenue and $2.03 EPS, showcasing STERIS's ability to maintain growth post-Dental segment divestiture |
Strategic Realignment | Dental segment sale for $800M reshapes STERIS's profile, allowing focus on core competencies and potential for operational efficiencies |
Market Valuation | Analysts set price targets around $265, reflecting STERIS's premium position in MedTech sector, despite challenges in maintaining growth rates |
Metrics to compare | STE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSTEPeersSector | |
---|---|---|---|---|
P/E Ratio | 35.0x | 77.7x | −0.7x | |
PEG Ratio | −1.75 | 1.45 | 0.00 | |
Price/Book | 3.1x | 4.5x | 2.6x | |
Price / LTM Sales | 3.9x | 4.1x | 3.2x | |
Upside (Analyst Target) | 19.0% | 0.0% | 47.1% | |
Fair Value Upside | Unlock | 7.3% | 7.3% | Unlock |